Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10083949

Sexual predators.

H V Zonana·M A Norko
View original source ↗Export metadata ↓

Abstract

Social responses to sex-offending behaviors have included criminal sanctions and clinical interventions that have evolved over time. These developments have created various challenges for mental health professionals charged with providing care to offenders, particularly when legislative expectations have exceeded available treatments. A summary is provided of recent clinical developments in assessments, therapies, and pharmacology. The usefulness of SRIs, in particular, may prompt the involvement of more psychiatrists in this treatment. Other implications for future practice of these clinical and legal developments are also discussed.

Explore related subjects

Androgen AntagonistsCognitive Behavioral TherapyDisruptive, Impulse Control, and Conduct DisordersFemaleHospitalizationHumansImagery, PsychotherapyMaleParaphilic DisordersPersonality DisordersPsychiatryRecurrenceReferral and ConsultationSelective Serotonin Reuptake InhibitorsSex OffensesUnited StatesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H V Zonana, M A Norko. 1999. Sexual predators.. https://doi.org/10.1016/s0193-953x(05)70063-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma.

BACKGROUND: We quantified changes in prostate carcinoma vascularity treated with anti-androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist. METHODS: Thirty-six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist((R)) (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre-enhancement scores, arrival time, time to peak, peak value, and area under the time-enhancement curve (AUC). These were compared to pre-treatment values and serial PSA measurements. RESULTS: The pre-enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68% +/- 9% (mean +/- standard error) by week 1, 56% +/- 9% by week 3, and 20% +/- 4% by week 6. A strong correlation with changes in the mean PSA (r = 0.95, P < 0.001) was also measured. In four patients, Doppler indices did not fall with PSA: two patients with the most marked discrepancy relapsed at 6 months. CONCLUSION: The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment.

Androgen Antagonists↗
PubMed2002

Comparison of antiandrogenic activities of vinclozolin and D,L-camphorquinone in androgen receptor gene transcription assay in vitro and mouse in utero exposure assay in vivo.

A chemical substance used as a photoinitiator for light-cure resin compositions, D,L-camphorquinone (CQN) was found to be weakly antiandrogenic in vitro. It competitively antagonized dihydrotestosterone (DHT)-induced transcriptional activity on the yeast-based androgen receptor gene transcription assay (YAA). Antiandrogenic activity of CQN was shown at higher concentration than 10(-4) M while the well-known antiandrogen, vinclozolin (VCZ) showed the activity at concentrations of 10(-6) M and above in YAA. The antiandrogenic activity of CQN was reconfirmed in the human cell line-based androgen receptor gene transcription assay (HCAA). To determine whether CQN affect male reproductive development, CQN or VCZ was administered to pregnant mice daily from gestational days 10 to 18 by gavage. In utero exposure to VCZ at 100 mg/kg/day caused a significant decrease in anogenital distance (AGD) of F1 neonates and reduced spermatogenesis in F1 males at 42 days of age. In contrast, maternal doses (100 and 300 mg/kg/day) of CQN had no affect on these endpoints in F1 offspring. Further, VCZ or CQN had no adverse affect on F1 male fertility. From these observations, CQN is potentially antagonistic to androgen receptor (AR) in vitro, but is estimated to be less antiandrogenic in vivo when it is administered to pregnant mice by gavage. Furthermore, these findings are the first to demonstrate that VCZ exerts significant antiandrogenic effects on reproductive tract development during gestation in mice.

Androgen Antagonists↗
PubMed2002

Lack of antiandrogenic effects in adult male rats following acute exposure to 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene (p,p'-DDE).

Although the insecticide dichlorodiphenyltrichloroethane (DDT) was banned in the US in 1972, DDT and its major metabolite 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene (DDE) are still persistent in the environment. DDE at high doses is antiandrogenic in fetal and adult rats and, therefore, is of concern in humans exposed environmentally. The objective of this work was to determine the dose-response relationship between DDE and its antiandrogenic effect in adult, male rats and to quantitate the concentration of DDE in tissues following oral exposures. Adult, male, Long-Evans rats (11-13 weeks) were castrated, implanted with testosterone capsules, and dosed by oral gavage with 0, 5, 12.5, 25, 50, or 100 mg DDE per kg body weight (BW) per day in corn oil for 4 days. On day 5 the rats were euthanized and liver, adrenals, ventral prostate, and seminal vesicles were weighed as a measure of response to DDE exposure. Blood, adrenals, brain, fat, kidney, lung, liver, muscle, ventral prostate, seminal vesicles, and skin were analyzed for DDE concentrations. Testosterone and dihydrotestosterone were measured in serum. There was a decrease in prostate weight that was not dose dependent; only the prostate weights in rats treated with 12.5 mg DDE per kg BW per day were reduced significantly compared to controls. The liver displayed a dose-dependent increase in weight that was significantly greater than control at DDE doses of 25, 50, and 100 mg/kg BW per day. Blood concentrations of DDE ranged from 0.32 to 11.3 ppm, while tissue concentrations ranged from 0.72 to 2620 ppm with the highest concentration in fat. Although DDE concentrations in the androgen-responsive tissues were higher than concentrations previously shown in vitro to inhibit androgen-receptor transcriptional activity, these concentrations did not appear to be antiandrogenic in vivo. The doses administered to the rats in this study are at least 10(5)-fold greater than the daily, average of human dietary intake of DDE.

Androgen Antagonists↗